Assembly Biosciences Files 8-K

Ticker: ASMB · Form: 8-K · Filed: 2024-12-26T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-statements

TL;DR

ASMB filed an 8-K on 12/26/24. Standard corporate update.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on December 26, 2024, reporting other events and financial statements. The company, formerly known as Ventrus Biosciences Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which provides transparency to investors about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any significant new risks or material adverse information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Assembly Biosciences, Inc.?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of December 26, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on December 26, 2024.

What was Assembly Biosciences, Inc. formerly known as?

Assembly Biosciences, Inc. was formerly known as Ventrus Biosciences Inc.

In which state is Assembly Biosciences, Inc. incorporated?

Assembly Biosciences, Inc. is incorporated in Delaware.

What is the business address of Assembly Biosciences, Inc.?

The business address of Assembly Biosciences, Inc. is Two Tower Place, 7th Floor, South San Francisco, California 94080.

From the Filing

0000950170-24-139962.txt : 20241226 0000950170-24-139962.hdr.sgml : 20241226 20241226082541 ACCESSION NUMBER: 0000950170-24-139962 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20241226 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241226 DATE AS OF CHANGE: 20241226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 241576444 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20241226.htm 8-K 8-K false 0001426800 0001426800 2024-12-26 2024-12-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On December 26, 2024, Assembly Biosciences, Inc. (the "Company") issued a press release announcing interim results from its ongoing Phase 1b clinical study evaluating its investigational next-generation capsid assembly modulator candidate ABI-4334 in participants with chronic hepatitis B virus infection. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits .   Exhibit Number Description 99.1 Press Release dated December 26, 2024.  104 Cover Page Interactive Data File (embedded within the Inline XBRL document)   1   S

View on Read The Filing